Sofosbuvir (SOF) and weight-based ribarivin (RBV) represented until recently the standard of care in hepatitis C virus (HCV) genotype (GT)2 patients. In registration studies 12-16weeks duration were associated with a 90% sustained virological response at 12weeks (SVR12). Real life cohorts showed lower SVR12 rates.
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience
Palmieri, VincenzoMembro del Collaboration Group
;
2017-01-01
Abstract
Sofosbuvir (SOF) and weight-based ribarivin (RBV) represented until recently the standard of care in hepatitis C virus (HCV) genotype (GT)2 patients. In registration studies 12-16weeks duration were associated with a 90% sustained virological response at 12weeks (SVR12). Real life cohorts showed lower SVR12 rates.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017 J Hepatol.pdf
non disponibili
Descrizione: articolo principale
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
701.68 kB
Formato
Adobe PDF
|
701.68 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Mangia Sofosbuvir .pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
566.24 kB
Formato
Adobe PDF
|
566.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
